Context Therapeutics (NASDAQ:CNTX – Get Free Report) released its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, reports.
Context Therapeutics Stock Up 3.3 %
CNTX traded up $0.03 during trading on Friday, hitting $0.80. 15,405 shares of the stock were exchanged, compared to its average volume of 387,480. The firm has a market capitalization of $59.70 million, a P/E ratio of -0.87 and a beta of 2.06. The stock has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $1.45. Context Therapeutics has a 1-year low of $0.64 and a 1-year high of $2.75.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on CNTX. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a report on Friday. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a report on Friday. Finally, JMP Securities initiated coverage on shares of Context Therapeutics in a report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $6.17.
About Context Therapeutics
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- What Are Dividends? Buy the Best Dividend Stocks
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- How to Read Stock Charts for Beginners
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
